Gössinger H D, Siostrzonek P, Mösslacher H
First Department of Medicine, University of Vienna, Austria.
Int J Cardiol. 1990 Mar;26(3):380-2. doi: 10.1016/0167-5273(90)90101-a.
We determined the effects of combined sotalol (160 mg/day) and flecainide (200 mg/day) in 15 patients with the Wolff-Parkinson-White syndrome. After medication given for 3 days, the plasma levels were 0.8 +/- 0.3 micrograms/ml for sotalol and 232 +/- 104 ng/ml for flecainide. Electrophysiologic testing showed complete blockade of the accessory pathway in 4 patients and a decrease in the anterograde conduction capacity by 27% in the remainder. The effect on the accessory pathway was unrelated to the resting conduction properties. Initiation of circus movement tachycardia was prevented in 5 of 11 patients. During a median period of 28 months of follow-up, 87% of patients were either free of tachycardia or satisfactorily improved. No proarrhythmic or adverse drug effects were observed.
我们确定了索他洛尔（160毫克/天）和氟卡尼（200毫克/天）联合用药对15例预激综合征患者的影响。用药3天后，索他洛尔的血浆浓度为0.8±0.3微克/毫升，氟卡尼为232±104纳克/毫升。电生理检查显示，4例患者的旁路完全阻滞，其余患者的前向传导能力下降27%。对旁路的影响与静息传导特性无关。11例患者中有5例的折返性心动过速发作得到预防。在中位随访期28个月期间，87%的患者无心动过速发作或病情得到满意改善。未观察到促心律失常或药物不良反应。
